×

Access all guidelines and regulatory updates on

QuriousRI
×

Access all guidelines and regulatory updates on

QuriousRI

Artixio

QuriousRI-GP – Regulatory Strategy and Planning Tool

QuriousRI-GP – Leading Regulatory Strategy & Planning Platform

Simulate diverse and complex regulatory scenarios across leading markets worldwide for your pharmaceutical, biologics, medical devices, radipharmceutical and combination products. Leverage Artixio’s regulatory intelligence database, QuriousRI, latest regulatory updates, analysis of regulatory pathways in key markets for all applications (new drugs, abbreviated pathways, lifecycle, paediatric, orphan drug), documentation requirements based on reference drugs / predicate products approved in the target markets. Build your regulatory roadmap seamlessly with Artixio expert driven regulatory insights.

Visualize Your Regulatory Strategy

Verify Novelty Analyse competitor drugs approved in the target markets to establish novelty
Define Pathway Assess applicable pathways based on local regulations and reference / predicate products
Assess Requirements Deep dive into regulatory requirements following the pathway including local testing, characterization and stability requirements
Assess Documentation Surf the comprehensive list of documents required per regulatory requirements including those requiring translation and legalization
Compare Streamline your global strategy comparing pathways and documentation required across multiple countries
Mitigate Gaps Use your approved or existing dossier against target market requirements to find gaps. Leverage Artixio’s insights for mitigation of gaps

Global Product Lifecycle and Portfolio Management Dashboard

Set up your portfolio of products across countries, therapy areas, formulations, strengths, routes of administration, new registrations, lifecycle maintenance (variations, renewals, withdrawals, recalls, line extensions) in a global dashboard. Track their status and plan for continued compliance and supply chain management.

Regulator Intelligence Agents

Leverage RI-Agents trained on set of data to find structured answers to your regulatory queries. The agents are trained on global regulatory guidelines coupled with Artixio’s experience in successfully managing compliance for life sciences products worldwide.
Chat with documents to prepare summaries, answer specific questions and augment your regulatory strategy with key insights.
Get in touch with our team to explore QuiriousRI-GP and start your regulatory strategy and planning journey with Artixio.
Should you wish to develop custom solutions for your specific needs, our in house team of artificial intelligence engineers and data scientists can help you build one, Fast and Efficient.

FAQs

What are the features of QuriousRI-GP?

QuriousRI-GP offers end to end life sciences (pharma, devices, biologics etc.) product lifecycle management strategy and planning solutions to prepare submission documents for health authorities worldwide. It also helps tracking the products status worldwide from planning to gap analysis, dossier preparation, submission, approval and post approval lifecycle maintenance. It offers assessment of reference and predicate products in the markets, applicable regulatory pathways, regulatory requirements in target countries, documentation requirements, comparison of multiple countries and perform gap analysis of documents.

All the key markets across APAC, LATAM are covered in the tool currently such as Thailand, Malaysia, China, Japan, Hong Kong, Brazil, Mexico and others.
QuiriousRI-GP’s underlying analytics is based in Artixio Team’s decades of regulatory experience in successfully registering new complex products and maintaining compliance. In addition, integration of guidelines, and updates coupled with Artixio’s case studies and regulatory intelligence database helps build the reliable decision support engine for the platform.

Industries We Serve

Pharmaceuticals

MedTech

Cosmetics

Nutrition

Biologics

Veterinary

Our Global Reach: Serving Life
Sciences Clients Worldwide

India

Singapore

Mexico

Brazil

Vietnam

Malaysia

Argentina

Colombia

Taiwan

China

Europe

Thailand

Indonesia

Philippines

USA

Japan

Qatar

South Korea

Insights from Artixio - Tips & Article

Orphan Drug Designation in South Korea (MFDS)

Orphan Drug Designation in

Orphan Drug Designation (ODD) is regulated by Ministry of Food and Drug Safety (MFDS)...

February 10, 2026
Artificial Intelligence (AI) and Machine Learning (ML) in Drug Discovery

Artificial Intelligence (AI) and

Artificial Intelligence (AI) and Machine Learning (ML) in drug discovery offer new possibilities for...

November 5, 2025
Competitive Intelligence for a Global Anti-Depressant Drug Manufacturer

Competitive Intelligence for a

Artixio’s competitive intelligence experts are seasoned in developing comprehensive strategy across therapeutic areas, treatment...

October 1, 2025